This company listing is no longer active
Horizon Therapeutics Future Growth
Future criteria checks 4/6
Key information
20.2%
Earnings growth rate
20.9%
EPS growth rate
Biotechs earnings growth | 25.3% |
Revenue growth rate | 9.3% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 02 Mar 2023 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 5,029 | 1,207 | 1,720 | 2,270 | 10 |
12/31/2024 | 4,531 | 1,138 | 1,485 | 2,018 | 12 |
12/31/2023 | 3,962 | 812 | 1,189 | 1,794 | 10 |
12/31/2022 | 3,629 | 521 | 1,132 | 1,258 | N/A |
9/30/2022 | 3,701 | 574 | 1,271 | 1,370 | N/A |
6/30/2022 | 3,813 | 765 | 1,271 | 1,415 | N/A |
3/31/2022 | 3,769 | 862 | 1,108 | 1,255 | N/A |
12/31/2021 | 3,226 | 534 | 907 | 1,035 | N/A |
9/30/2021 | 2,957 | 552 | 734 | 907 | N/A |
6/30/2021 | 2,557 | 518 | 492 | 604 | N/A |
3/31/2021 | 2,187 | 280 | 515 | 615 | N/A |
12/31/2020 | 2,200 | 390 | 356 | 556 | N/A |
9/30/2020 | 1,819 | 792 | 197 | 337 | N/A |
6/30/2020 | 1,518 | 517 | 185 | 316 | N/A |
3/31/2020 | 1,376 | 592 | 173 | 308 | N/A |
12/31/2019 | 1,300 | 573 | 408 | 426 | N/A |
9/30/2019 | 1,292 | 82 | 328 | 344 | N/A |
6/30/2019 | 1,282 | 97 | 330 | 341 | N/A |
3/31/2019 | 1,264 | 77 | 306 | 312 | N/A |
12/31/2018 | 1,208 | -38 | 178 | 195 | N/A |
9/30/2018 | 1,126 | -178 | 216 | 229 | N/A |
6/30/2018 | 1,073 | -275 | 198 | 213 | N/A |
3/31/2018 | 1,059 | -460 | 183 | 199 | N/A |
12/31/2017 | 1,056 | -350 | 280 | 284 | N/A |
9/30/2017 | 1,092 | -495 | 275 | 280 | N/A |
6/30/2017 | 1,029 | -437 | 335 | 341 | N/A |
3/31/2017 | 997 | -212 | 330 | 340 | N/A |
12/31/2016 | 981 | -166 | 354 | 369 | N/A |
9/30/2016 | 915 | -12 | N/A | 365 | N/A |
6/30/2016 | 933 | -3 | N/A | 325 | N/A |
3/31/2016 | 849 | 14 | N/A | 319 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: H1ZN34's forecast earnings growth (20.2% per year) is above the savings rate (9.6%).
Earnings vs Market: H1ZN34's earnings (20.2% per year) are forecast to grow faster than the BR market (7.6% per year).
High Growth Earnings: H1ZN34's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: H1ZN34's revenue (9.3% per year) is forecast to grow faster than the BR market (6.1% per year).
High Growth Revenue: H1ZN34's revenue (9.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if H1ZN34's Return on Equity is forecast to be high in 3 years time